Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
暂无分享,去创建一个
F. Lund-Johansen | J. Jahnsen | A. Tveter | A. Chopra | S. Mjaaland | T. Kvien | J. Sexton | G. Goll | D. Warren | E. Haavardsholm | L. Munthe | L. S. Nissen-Meyer | J. Vaage | T. Tran | S. Syversen | S. Provan | G. Grødeland | K. Jørgensen | P. Ricanek | G. B. Kro | I. Jyssum | A. M. Andersson | L. S. Nissen‐Meyer | S. W. Syversen
[1] S. Subhadarshani,et al. Clinical Images: Hydroxyurea‐induced dermatomyositis‐like rash , 2022 .
[2] D. Follmann,et al. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.
[3] F. Lund-Johansen,et al. Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera , 2022 .
[4] J. Izopet,et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients , 2021, American Journal of Transplantation.
[5] F. Lund-Johansen,et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study , 2021, The Lancet Rheumatology.
[6] D. Weinberger,et al. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. , 2021, JAMA internal medicine.
[7] T. Harrer,et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[8] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[9] M. Davenport,et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.
[10] J. Gottenberg,et al. Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab , 2021, The Lancet Rheumatology.
[11] S. Higa,et al. Rapid attenuation of anti-SARS-CoV-2 antibody in patients with musculoskeletal diseases who reinitiated intensive immunosuppressive therapies after COVID-19. , 2021, Arthritis & rheumatology.
[12] F. Lund-Johansen,et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[13] D. McGovern,et al. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease , 2021, Annals of Internal Medicine.
[14] B. Ludewig,et al. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses , 2021, The Lancet Rheumatology.
[15] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[16] J. Albayda,et al. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series , 2021, Annals of the Rheumatic Diseases.
[17] J. Curtis,et al. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.
[18] Gregory F. Wu,et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.
[19] L. Heylen,et al. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.
[20] M. Neurath,et al. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. , 2021, The New England journal of medicine.
[21] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 , 2021, Arthritis & rheumatology.
[22] N. Kennedy,et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis , 2021, Autoimmunity Reviews.
[23] M. Boers,et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies , 2021, The Lancet Rheumatology.
[24] P. Gallian,et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] M. Dubinsky,et al. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease , 2021, Gastroenterology.
[26] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[27] D. McGovern,et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease , 2021, The American journal of gastroenterology.
[28] D. Swerdlow,et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.
[29] Colin Simpson,et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study , 2021, The Lancet.
[30] C. Lees,et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab , 2021, Gut.
[31] L. Peyrin-Biroulet,et al. SARS-CoV-2 vaccination in IBD: more pros than cons , 2021, Nature Reviews Gastroenterology & Hepatology.
[32] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[33] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[34] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[35] F. Underwood,et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.
[36] Karl Erik Müller,et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients , 2020, Proceedings of the National Academy of Sciences.
[37] A. Vojdani,et al. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.
[38] Xinquan Wang,et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.
[39] E. S. El-Din,et al. Hydroxyurea‐induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis‐like eruption? , 2012, International journal of dermatology.
[40] J. Ellenberg,et al. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.
[41] J. Callen,et al. Hydroxyurea-induced dermatomyositis-like eruption. , 2003, Journal of the American Academy of Dermatology.
[42] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[43] R. F. Harvey,et al. A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.